Ningping Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ningping Feng has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
- Timothy P. Heffernan
TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, USA
46 shared publications - Christopher A. Bristow
The University of Texas MD Anderson Cancer Center 4 Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division Houston, Texas
28 shared publications Joseph R. Marszalek
28 shared publicationsChristopher A. Bristow
27 shared publications- Alessandro Carugo
Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
23 shared publications - Allison L. Creason
Oregon Health & Science University
23 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Mutation and sequence alterations from whole exome sequencing of in vitro models of acquired resistance to MRTX1133.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Mutation and sequence alterations from whole exome sequencing of in vitro models of acquired resistance to MRTX1133.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRASG12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRASG12D cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRASG12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRASG12D cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Characterization of acquired resistance to KRASG12C inhibition across studies and cancer types.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Characterization of acquired resistance to KRASG12C inhibition across studies and cancer types.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 7A: Clinical evaluation and characterisitcs of KPC mice treated until clinical endpoint. Supplemental Table 7B: Clinical evaluation and characterisitcs of KPC mice treated for 3 days.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 9 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of reagents and antibodies used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 9 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of reagents and antibodies used in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
MRTX1133 sensitivty across the PRISM cohort of cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
MRTX1133 sensitivty across the PRISM cohort of cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figures 1-11 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Figure 1: Acquired resistance to KRASG12C inhibition in PDAC and other GI cancers. Supplemental Figure 2: MRTX1133 sensitivity across KRASG12D mutant in vitro models of PDAC. Supplemental Figure 3: Isogenic models of acquired resistance to MRTX1133. Supplemental Figure 4: In vivo treatment and tumor monitoring for the KPC PDAC mouse model. Supplemental Figure 5: Genomic characterization of KPC tumors. Supplemental Figure 6: snRNA-seq quality metrics and description of the tumor microenvironment. Supplemental Figure 7: Identification and characterization of malignant cell populations. Supplemental Figure 8: Characterization of malignant metaprograms in KPC tumors. Supplemental Figure 9: Treatment with MRTX1133 induces modest changes in the immune microenvironment following tumor regression. Supplemental Figure 10: Treatment of 6694C2-LM tumors with MRTX1133 reduces granulocytes but has little effect on T cells. Supplemental Figure 11: Neoadjuvant and adjuvant therapy in a metastatic model of PDAC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures 1-11 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Supplemental Figure 1: Acquired resistance to KRASG12C inhibition in PDAC and other GI cancers. Supplemental Figure 2: MRTX1133 sensitivity across KRASG12D mutant in vitro models of PDAC. Supplemental Figure 3: Isogenic models of acquired resistance to MRTX1133. Supplemental Figure 4: In vivo treatment and tumor monitoring for the KPC PDAC mouse model. Supplemental Figure 5: Genomic characterization of KPC tumors. Supplemental Figure 6: snRNA-seq quality metrics and description of the tumor microenvironment. Supplemental Figure 7: Identification and characterization of malignant cell populations. Supplemental Figure 8: Characterization of malignant metaprograms in KPC tumors. Supplemental Figure 9: Treatment with MRTX1133 induces modest changes in the immune microenvironment following tumor regression. Supplemental Figure 10: Treatment of 6694C2-LM tumors with MRTX1133 reduces granulocytes but has little effect on T cells. Supplemental Figure 11: Neoadjuvant and adjuvant therapy in a metastatic model of PDAC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Genetic and copy number variants at resistance to adagrasib or sotorasib across the novel cohort of PDAC and GI cancer patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Genetic and copy number variants at resistance to adagrasib or sotorasib across the novel cohort of PDAC and GI cancer patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 8 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of genes in each NMF metaprograms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 8 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
List of genes in each NMF metaprograms